The randomised, open-label, crossover clinical study evaluated the pharmacokinetics of Lipomac compared with conventional non-liposomal vitamin C in 12 healthy adult subjects. Results showed significantly higher systemic exposure following Lipomac supplementation, confirming enhanced absorption, improved gastrointestinal transit, and prolonged vitamin C circulation.
These findings provide robust human evidence supporting liposomal delivery as an effective strategy to overcome the inherent absorption limitations associated with conventional vitamin C formulations.
Why liposomal delivery matters
Conventional vitamin C is highly susceptible to chemical and enzymatic degradation in the digestive tract, limiting the amount that ultimately reaches systemic circulation. Liposomal delivery systems encapsulate the active ingredient within biocompatible phospholipid vesicles, offering:
- Enhanced intestinal absorption
- Protection from chemical and enzymatic degradation
- Improved delivery into systemic circulation
Clinical study highlights
- Randomised, open-label, cross-over design
- Conducted in 12 healthy adult subjects
- Compared Lipomac liposomal vitamin C with standard non-liposomal vitamin C
- Demonstrated markedly higher bioavailability and systemic exposure with Lipomac
Leadership perspectives
Mr Gaurav Soni, Founder and Managing Director, said:
“Lipomac showcases our commitment to clinically backed innovation and strengthens our position as a science-forward partner to global nutraceutical brands.”
Mr Madhu Krishnamani, Founder and Managing Director, added:
“We are proud to advance health-focused solutions grounded in evidence and designed to deliver meaningful value to consumers worldwide.”
Scientific leadership perspective
Commenting on the findings, Dr. H. N. Shiv, Chief Scientific Officer at Botanic Healthcare, said:
“These findings validate the core scientific engineering behind DFS Technology™ and reinforce the measurable performance advantages of liposomal formats.”
Strengthening evidence-based innovation
The publication of this clinical data further strengthens Botanic Healthcare’s growing portfolio of evidence-driven nutraceutical ingredients and underscores its commitment to translating advanced delivery technologies into clinically meaningful health solutions for global partners.